Beam Therapeutics (BEAM) EBT Margin (2019 - 2026)
Beam Therapeutics' (BEAM) quarterly EBT Margin came in at 309.75% in Q1 2026, up 115661.0% year-on-year from N/an in Q1 2025, and down 244.68% on a QoQ basis from 214.09% in Q4 2025.
Beam Therapeutics (BEAM) EBT Margin (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of EBT Margin data on file, last reported at 309.75% in Q1 2026.
- On a quarterly basis, EBT Margin rose 115661.0% year-over-year to 309.75% in Q1 2026; TTM through Mar 2026 was 42.09%, a 56751.0% increase from a year earlier, with the FY2025 full-year figure at 57.24%, up 53582.0% from the prior year.
- EBT Margin for Q1 2026 stood at 309.75%, down from 214.09% in the prior quarter.
- Over the last five years, EBT Margin for BEAM reached as high as 214.09% in Q4 2025 and fell as low as 1466.36% in Q1 2025.
- Historically, EBT Margin has averaged 654.34% across 5 years, with a median of 558.88% in 2023.
- Across the five-year window, EBT Margin jumped 336684900 bps in 2022 and slumped 88288 bps in 2024, its largest moves.
- Year by year, EBT Margin stood at 186.4% in 2022, then jumped by 124 bps to 45.59% in 2023, then tumbled by 759 bps to 300.51% in 2024, then jumped by 171 bps to 214.09% in 2025, then plunged by 245 bps to 309.75% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 309.75% in Q1 2026, 214.09% in Q4 2025, and 1162.38% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | -309.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -309.75% |
| Dec 31, 2025 | 214.09% |
| Sep 30, 2025 | -1,162.38% |
| Jun 30, 2025 | -1,208.26% |
| Mar 31, 2025 | -1,466.36% |
| Dec 31, 2024 | -300.51% |
| Sep 30, 2024 | -677.47% |
| Jun 30, 2024 | -773.12% |
| Mar 31, 2024 | -1,251.15% |
| Dec 31, 2023 | 45.59% |
| Sep 30, 2023 | -558.88% |
| Jun 30, 2023 | -411.49% |
| Mar 31, 2023 | -368.26% |
| Dec 31, 2022 | -186.40% |
| Sep 30, 2022 | -516.90% |
| Jun 30, 2022 | -1,058.13% |
| Mar 31, 2022 | -1,134.33% |
| Dec 31, 2021 | -126.71% |
| Sep 30, 2021 | -3,685.19% |
| Jun 30, 2021 | -1,022,266.67% |